Subject:
- Active Substance: Icosapent ethyl
- Name: Vazkepa®
- Therapeutic area: Dyslipidemia
- Pharmaceutical company: Amarin Pharmaceuticals Ireland Limited
Time table:
- Start: 01.09.2021
- Final decision by G-BA: 17.02.2022
Final decision:
- No additional benefit proved